Immutep Ltd ( (AU:IMM) ) just unveiled an announcement.
Immutep Ltd has announced the successful dosing of the first patient in its pivotal TACTI-004 Phase III trial for first-line non-small cell lung cancer (1L NSCLC). This milestone is significant for the company as it seeks to leverage its product, efti, in combination with KEYTRUDA to improve survival rates for patients. The trial targets a large patient population that does not respond to current monotherapies, presenting a potential blockbuster opportunity if successful. The combination therapy aims to expand the number of patients who respond to treatment, improve clinical outcomes, and overcome resistance, potentially reshaping the treatment landscape for NSCLC.
More about Immutep Ltd
Immutep Ltd operates in the biotechnology industry, focusing on developing immunotherapy treatments for cancer. The company’s primary product, efti, is designed to enhance the efficacy of immune checkpoint inhibitors like KEYTRUDA, aiming to improve patient outcomes in oncology, particularly in non-small cell lung cancer (NSCLC).
YTD Price Performance: -9.09%
Average Trading Volume: 5,000
Technical Sentiment Signal: Strong Buy
Current Market Cap: $220.2M
Learn more about IMM stock on TipRanks’ Stock Analysis page.